

## ANSWERING REVIEWERS

Mar 15, 2016

Dear Editor,



Please find enclosed the edited manuscript in Word format (24862-Revised manuscript.doc).

**Title:** Dendritic cell-based cancer immunotherapy for colorectal cancer

**Author:** Mikio Kajihara, Kazuki Takakura, Tomoya Kanai, Zensho Ito, Keisuke Saito, Shinichiro Takami, Shigetaka Shimodaira, Masato Okamoto, Toshifumi Ohkusa, Shigeo Koido

**Name of Journal:** World Journal of Gastroenterology

**Manuscript Type:** TOPIC HIGHLIGHT

**ESPS Manuscript NO:** 24862

**Invited ID:** 02061468.

The manuscript has been improved according to the suggestions:

### Reviewer #1

(1) This is a very good written review of the use of the properties of dendritic cells. The authors state that the primary mode of tumor killing after dendritic cell therapy is the T Cell. Some studies have also demonstrated the importance of the NK cell or NKT cell in this role as well - the authors should revise this section of the manuscript to state this.

**(Response)** As suggested, we had demonstrated the importance of the NK and NKT cell in DC-based cancer vaccines in the text and Table 1.

(2) The authors mentioned that "Major histocompatibility complex (MHC) class I molecules on cancer cells bound to antigenic peptide derived from tumor-associated antigens (TAAs) are recognized by the TCR of CD8<sup>+</sup> T cells." Please cite some references to enhance the descriptions.

**(Response)** As suggested, we had cited reference in this sentence.

(3) To be a complete review, a section of the PDL-1 or PD-1 that has been used in colorectal cancer could be reviewed and summarized in a table.

**(Response)** As suggested, we had demonstrated the results of a clinical trial using PD-1 antibody in text and Table 2.

#### **Reviewer #2**

In the article, it was aimed to discuss the possibility of antitumor immune responses by blocking the immunoinhibitory PD-1/PD-L1 pathway for CRC patients. The subject is interesting and written well. The article may be useful for people working in related fields.

**(Response)** Thank you very much for reviewing and your comments. We are so happy that we can be able to share with you our opinion.

#### **Reviewer #3**

This is a well-written and informative review article. There are no major scientific flaws and I think reviewers will find it very informative and useful. This manuscript can be published without any changes.

**(Response)** Thank you very much for reviewing and your comments. We are so happy that we can be able to share with you our opinion.

Our manuscript was edited and formatted to *World Journal of Gastroenterology* style by American Journal Experts: <http://www.journalexperts.com> and cross checked.

We are enclosing the entire revised manuscript and Tables. The underline in the manuscript indicates the changes.

We do appreciate the time and effort that the reviewers have put into helping us with this manuscript and we hope that it is now suitable for publication in *World Journal of Gastroenterology*.

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

*Shigeo Koido*

Shigeo Koido, M.D.

Division of Gastroenterology and Hepatology,

Department of Internal Medicine,

The Jikei University School of Medicine, Tokyo, Japan

163-1 Kashiwa-shita Kashiwa, Chiba 277-8564 Japan.

**Fax:** +81-4-7163-3488.

Shigeo\_koido@jikei.ac.jp